IceCure to Report First Half 2025 Financial and Operating Results on August 13, 2025PRNewsWire • 08/06/25
IceCure Announces Expiration and Results of Approximately Two Times Over-Subscribed Rights Offering for Aggregate Gross Proceeds of $10.0 MillionPRNewsWire • 07/29/25
IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with CryoablationPRNewsWire • 07/25/25
IceCure Reminds Shareholders of Upcoming Expiration of Rights Offering Subscription PeriodPRNewsWire • 07/24/25
IceCure Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025PRNewsWire • 07/03/25
IceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient OutcomesPRNewsWire • 06/09/25
IceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025PRNewsWire • 05/21/25
IceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense® CryoablationPRNewsWire • 05/06/25
IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast CancerPRNewsWire • 04/30/25
IceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging SymposiumPRNewsWire • 04/28/25
IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer CryoablationPRNewsWire • 04/22/25
IceCure Medical Stock Dips Despite Positive ICESECRET Study ResultsZacks Investment Research • 03/28/25
IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North AmericaPRNewsWire • 03/27/25
IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free RatePRNewsWire • 03/24/25
IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025PRNewsWire • 03/21/25
IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast CancerPRNewsWire • 03/20/25
IceCure's ProSense® Cryoablation Featured in Six Studies Presented at St. Gallen International Breast Cancer ConferencePRNewsWire • 03/18/25